Eli Lilly is usually described as Danish firm Novo Nordisk's archrival when it comes to weight-loss drugs.
The announcement comes ahead of Eli Lilly's quarterly report for the start of the year, which is expected on Thursday.
New York-based Ajax Therapeutics is focused on developing a new generation of drugs for the treatment of blood cancer.
